

## d3 MEDICINE LLC AND VIROCLINICS BIOSCIENCES BV FORM VIROLOGY DRUG DEVELOPMENT ALLIANCE TO SERVE THE BIOPHARMACEUTICAL INDUSTRY

### NEWS RELEASE MESSAGING

#### *Key messages:*

- d3 Medicine and Viroclinics Biosciences believe strongly that the traditional model for development companies engaging CROs and consultants can be improved.
- CROs are usually engaged on an arms-length basis
- d3 Medicine and Viroclinics believe that optimal use of their combined expertise is realized when they are integrated into project teams rather than providing ad hoc arms-length advice around particular problems without hearing the views of the overall client project team and their external key advisors.
- d3 Medicine believes that there is great value in being able to offer our clients access to Viroclinics virology expertise which spans from early development through to post-marketing commitments and their external key advisors .
- Viroclinics believes that by working with d3 Medicine it can now offer its clients access to expertise in clinical pharmacology and clinical development to design innovative and adaptive drug development plans for both biologics and small molecule antiviral drugs which leverage data provided by Viroclinics virology services.
- Delivers more robust data packages to inform development strategies and provide valuable data to support both pricing and reimbursement negotiations and commercial transactions.